Problematic severe asthma Source: Eur Respir Mon 2012; 56: 22-39 Year: 2012
The association between airway and systemic eosinophilia and symptoms and exacerbations differ between asthma and COPD patients Source: Virtual Congress 2020 – Monitoring of inflammation in remodelling Year: 2020
The influence of obesity on bronchial hyperresponsiveness, airway and systemic inflammation, lung function and quality of life in patients with asthma Source: Annual Congress 2008 - Asthma: growing understanding of influential factors Year: 2008
Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with ongoing allergic rhinitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017
Same role and same treatment for airway eosinophilia in asthma and COPD? Source: Eur Respir J 2007; 29: 831-833 Year: 2007
Conclusion: clinical phenotypes of asthma Source: Annual Congress 2005 - Severe asthma: perception and management Year: 2005
Evaluation and management of difficult-to-control asthma Source: Annual Congress 2007 - PG1 - Asthma: from bench to bedside Year: 2007
Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges Year: 2009
Changes in symptoms, respiratory function, airway inflammation, and airway hyperresponsiveness over 10 year of inhaled corticosteroid therapy in adult asthma patients Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015
Comparison of residual eosinophilic inflammation in the distal airway of patients with well-controlled asthma using different drug combinations of asthma treatment Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008
Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives Source: Eur Respir Rev 2015; 24: 594-601 Year: 2015
Modulation of airway inflammation to prevent exacerbations of COPD Source: Eur Respir Rev 2005; 14: 78-82 Year: 2005
The clinical, spirometric and cytological profiles of exacerbations in poorly controlled severe persistent asthmatics Source: Annual Congress 2007 - Towards controlling severe asthma Year: 2007
Airway pathology in asthma Source: Eur Respir J 2001; 18: 18S-23S Year: 2001
Clinical markers of disease severity in the assessment of airway inflammation in patients with persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 335s Year: 2001
Severe exacerbations predict excess lung function decline in asthma Source: Eur Respir J 2007; 30: 452-456 Year: 2007
Association between airway inflammation, disease control and lung function parameters in asthma Source: Annual Congress 2010 - Cough, airway hyperresponsiveness and asthma control Year: 2010
The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation Source: Eur Respir J 2004; 23: 464-476 Year: 2004
Systemic, upper and lower airway inflammation at exacerbation of COPD Source: Eur Respir J 2004; 24: Suppl. 48, 45s Year: 2004
Are we ready to monitor inflammation and remodelling in asthma? Source: Annual Congress 2005 - Inflammatory phenotypes of asthma and COPD: the end of traditional diagnosis, or not? Year: 2005